DPP-4 enzyme

DPP-4 enzyme. Dipeptidyl peptidase-4 is a transmembrane glycoprotein and serine exopeptidase that plays a crucial role in the inactivation of incretin hormones. Its discovery is linked to research on T cell activation and glucose metabolism. The enzyme's structure allows it to cleave N-terminal dipeptides from substrates with a proline or alanine at the penultimate position, influencing various physiological pathways.

Structure and function

The enzyme is a homodimer, with each subunit containing a short cytoplasmic tail, a transmembrane domain, and a large extracellular region. This extracellular region houses the catalytic site, which features a classic triad of serine, aspartate, and histidine residues common to serine proteases. The structure is stabilized by interactions with calcium ions and shares homology with other members of the prolyl oligopeptidase family. Its functional activity is dependent on its expression on the surface of various cell types, including endothelial cells, epithelial cells, and lymphocytes. The catalytic mechanism involves nucleophilic attack by the serine residue, leading to peptide bond hydrolysis and the release of dipeptides.

Physiological roles

A primary physiological function is the rapid degradation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, thereby regulating postprandial insulin secretion. Beyond metabolic control, it functions as the T-cell activation antigen CD26, playing a co-stimulatory role in immune response by interacting with adenosine deaminase and caveolin-1. The enzyme also processes various chemokines and neuropeptides, such as substance P and neuropeptide Y, modulating their activity in systems like the cardiovascular system and the nervous system. Its soluble form, found in blood plasma, retains enzymatic activity and contributes to systemic peptide hormone regulation.

Clinical significance

Dysregulation of this enzyme's activity is most prominently associated with type 2 diabetes mellitus, due to its role in incretin hormone metabolism. Elevated levels have been observed in conditions like obesity, non-alcoholic fatty liver disease, and certain autoimmune disorders, including rheumatoid arthritis and multiple sclerosis. Its role as CD26 links it to HIV infection, as it can act as a co-receptor for viral entry, and to the progression of certain cancers, such as mesothelioma and prostate cancer. Research from institutions like the National Institutes of Health has explored its potential as a biomarker for inflammatory bowel disease and heart failure.

Inhibitors and therapeutic use

Pharmacological inhibition of this enzyme is a established therapeutic strategy for type 2 diabetes mellitus. These inhibitors, known as gliptins, include sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin. They work by preventing the degradation of glucagon-like peptide-1, thereby enhancing glucose-dependent insulin secretion from pancreatic beta cells. Clinical trials, such as those leading to approval by the U.S. Food and Drug Administration and the European Medicines Agency, have demonstrated their efficacy in lowering glycated hemoglobin levels. They are often used in combination with other agents like metformin or sulfonylureas, and their safety profile is monitored for potential risks like acute pancreatitis and heart failure.

Research and development

Ongoing research, supported by organizations like the American Diabetes Association and the Juvenile Diabetes Research Foundation, explores the enzyme's roles beyond glycemic control. Studies investigate its involvement in stem cell mobilization, bone metabolism, and wound healing. Development of novel inhibitors continues, including dual-acting agents that target both this enzyme and the sodium-glucose cotransporter-2. Research presented at forums like the American Heart Association Scientific Sessions examines cardiovascular outcomes in patients using these drugs. Furthermore, its expression in tumors is being studied for potential applications in cancer immunotherapy and diagnostic imaging, with investigations underway at centers like the Memorial Sloan Kettering Cancer Center.

Category:Enzymes Category:Diabetes